HRMY Stock Price, Harmony Biosciences Holdings, . Quote, Chart

Market Summary

USD29.31-0.09

Delayedas of 22 Apr 2024, 10:54 am

-0.31%

HRMY Alerts

1 major insider sales recently.

HRMY Stock Price

View Fullscreen

HRMY RSI Chart

HRMY Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

12.95

Price/Sales (Trailing)

2.87

EV/EBITDA

7.77

Price/Free Cashflow

7.62

HRMY Price/Sales (Trailing)

HRMY Profitability

EBT Margin

29.79%

Return on Equity

27.59%

Return on Assets

15.88%

Free Cashflow Yield

13.13%

HRMY Fundamentals

HRMY Revenue

Revenue (TTM)

582.0M

Rev. Growth (Yr)

31.26%

Rev. Growth (Qtr)

5.08%

HRMY Earnings

Earnings (TTM)

128.9M

Earnings Growth (Yr)

-45.15%

Earnings Growth (Qtr)

-30.82%

Breaking Down HRMY Revenue

52 Week Range

28.8039.27

(Low)(High)

Last 7 days

-0.3%

Last 30 days

-12.6%

Last 90 days

-7.1%

Trailing 12 Months

-7.2%

How does HRMY drawdown profile look like?

HRMY Financial Health

Current Ratio

2.75

Debt/Equity

0.38

Debt/Cashflow

1.23

HRMY Investor Care

Buy Backs (1Y)

4.78%

Diluted EPS (TTM)

2.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	471.7M	498.9M	541.9M	582.0M
2022	331.1M	364.3M	400.8M	437.9M
2021	199.6M	235.4M	270.5M	305.4M
2020	44.4M	82.9M	121.3M	159.7M
2019	0	0	0	6.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Harmony Biosciences Holdings, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 29, 2024	kapadia sandip	acquired	-	-	15,000	chief financial officer
Mar 29, 2024	kapadia sandip	sold (taxes)	-269,077	33.58	-8,013	chief financial officer
Mar 15, 2024	dierks jeffrey	sold	-383,328	32.00	-11,979	chief commercial officer
Mar 15, 2024	dierks jeffrey	acquired	98,467	8.22	11,979	chief commercial officer
Mar 08, 2024	dierks jeffrey	sold	-6,208	32.00	-194	chief commercial officer
Mar 08, 2024	dierks jeffrey	acquired	1,594	8.22	194	chief commercial officer
Mar 29, 2023	kapadia sandip	sold (taxes)	-514,211	33.36	-15,414	chief financial officer
Mar 29, 2023	kapadia sandip	acquired	-	-	30,000	chief financial officer
Dec 14, 2022	nielsen jack	sold	-169,927	59.96	-2,834	-
Dec 14, 2022	wicki andreas	sold	-7,800	60.00	-130	-

Which funds bought or sold HRMY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	SJS Investment Consulting Inc.	reduced	-25.00	-29.00	101	-%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	28.00	739	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	1.14	57,972	1,184,430	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	reduced	-14.66	-61,081	480,429	0.03%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-34.64	-423,289	897,426	0.02%
Apr 12, 2024	Financial Synergies Wealth Advisors, Inc.	unchanged	-	-108	168	-%
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-32.00	-	-%
Apr 05, 2024	CWM, LLC	added	313	12,000	15,000	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	4.46	67,042	847,022	-%
Apr 05, 2024	GAMMA Investing LLC	added	46.32	1,672	4,668	-%

Are Funds Buying or Selling HRMY?

Are funds buying HRMY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HRMY

No. of Funds

HRMY Alerts

1 major insider sales recently.

Unveiling Harmony Biosciences Holdings, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	valor iv pharma holdings, llc	19.2%	11,218,033	SC 13G/A
Feb 13, 2024	vanguard group inc	6.27%	3,674,764	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 24, 2024	blackrock inc.	10.2%	6,002,374	SC 13G/A
Oct 06, 2023	blackrock inc.	10.2%	6,131,534	SC 13G/A
Feb 14, 2023	vivo capital viii, llc	4.3%	2,571,024	SC 13G/A
Feb 14, 2023	hbm healthcare investments (cayman) ltd.	3.6%	2,147,943	SC 13G/A
Feb 13, 2023	valor iv pharma holdings, llc	18.9%	11,218,033	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	5.49%	3,254,641	SC 13G

Recent SEC filings of Harmony Biosciences Holdings, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	8-K	Current Report
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 02, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 15, 2024	144	Notice of Insider Sale Intent
Mar 11, 2024	4	Insider Trading
Mar 08, 2024	144	Notice of Insider Sale Intent
Feb 28, 2024	10-K/A	Annual Report

Peers (Alternatives to Harmony Biosciences Holdings, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Harmony Biosciences Holdings, Inc. News

Latest updates

Harmony Biosciences Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																	(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	5.1%	168	160	134	119	128	117	107	85.00	91.00	81.00	74.00	60.00	56.00	46.00	38.00	20.00	-
Gross Profit	-2.1%	125	128	109	98.00	101	94.00	88.00	71.00	73.00	66.00	61.00	49.00	46.00	38.00	32.00	16.00	-
Operating Expenses	34.0%	85.00	63.00	62.00	58.00	54.00	82.00	55.00	43.00	45.00	45.00	38.00	35.00	38.00	27.00	24.00	26.00	-
S&GA Expenses	14.8%	27.00	23.00	25.00	23.00	21.00	20.00	20.00	18.00	19.00	16.00	17.00	16.00	18.00	13.00	12.00	13.00	-
R&D Expenses	73.2%	30.00	17.00	15.00	13.00	10.00	41.00	13.00	8.00	7.00	12.00	6.00	5.00	8.00	4.00	4.00	3.00	-
EBITDA Margin	-8.6%	0.34*	0.37*	0.31*	0.29*	0.28*	0.25*	0.22*	0.21*	0.19*	0.13*	0.22*	0.18*	-	-	-	-	-
Interest Expenses	63.3%	8.00	5.00	6.00	5.00	7.00	4.00	4.00	4.00	8.00	3.00	7.00	7.00	7.00	7.00	6.00	6.00	-
Income Taxes	-2.2%	13.00	13.00	10.00	8.00	-4.41	-79.98	6.00	2.00	-	-0.90	2.00	-	-	-	-	-	-
Earnings Before Taxes	-23.4%	40.00	52.00	44.00	38.00	44.00	8.00	29.00	23.00	24.00	-10.52	16.00	7.00	-0.21	2.00	-0.03	-38.62	-
EBT Margin	-9.2%	0.30*	0.33*	0.27*	0.25*	0.24*	0.21*	0.18*	0.16*	0.12*	0.05*	0.11*	0.05*	-	-	-	-	-
Net Income	-30.8%	27.00	38.00	34.00	29.00	49.00	88.00	24.00	21.00	23.00	-9.62	14.00	7.00	-0.21	2.00	-0.03	-38.62	-
Net Income Margin	-20.4%	0.22*	0.28*	0.40*	0.40*	0.41*	0.39*	0.16*	0.15*	0.11*	0.04*	0.10*	0.05*	-	-	-	-	-
Free Cashflow	21.3%	77.00	63.00	37.00	43.00	27.00	55.00	34.00	29.00	38.00	30.00	18.00	13.00	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	4.3%	811	778	760	715	674	643	505	464	433	391	360	337	427	320	107
Current Assets	-2.6%	451	463	456	418	400	382	323	280	284	241	205	178	263	250	31.00
Cash Equivalents	-4.0%	312	325	317	288	244	262	237	225	235	190	160	142	229	222	25.00
Inventory	5.4%	5.00	5.00	5.00	4.00	4.00	4.00	4.00	5.00	4.00	5.00	5.00	4.00	4.00	2.00	1.00
Net PPE	-13.3%	0.00	0.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	16.2%	344	296	275	272	271	300	259	250	247	239	233	229	330	226	118
Current Liabilities	45.7%	164	112	93.00	85.00	79.00	107	66.00	57.00	54.00	48.00	37.00	33.00	135	32.00	20.00
Long Term Debt	-2.0%	179	182	180	185	190	190	190	190	190	190	196	195	194	193	98.00
LT Debt, Current	0%	15.00	15.00	11.00	7.00	2.00	2.00	2.00	2.00	2.00	2.00	-	-	-	-	-
LT Debt, Non Current	-2.0%	179	182	180	185	190	190	190	190	190	190	196	195	194	193	98.00
Shareholder's Equity	-3.0%	467	481	485	443	403	344	247	215	187	152	127	108	97.00	95.00	-
Retained Earnings	15.7%	-143	-169	-208	-242	-272	-320	-408	-432	-453	-476	-466	-480	-488	-487	-422
Additional Paid-In Capital	-6.4%	610	652	694	686	675	665	655	647	640	628	593	589	585	583	-
Shares Outstanding	-3.1%	57.00	59.00	60.00	60.00	60.00	59.00	59.00	59.00	58.00	58.00	57.00	57.00	-	-	-
Float	-	-	-	1,175	-	-	-	1,360	-	-	-	731	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	21.5%	76,665	63,100	37,063	42,559	26,678	55,205	33,731	28,852	37,533	30,424	18,070	12,530	10,047	8,838	4,832	-26,702	-	-
Share Based Compensation	10.9%	8,863	7,991	7,648	7,203	7,260	7,007	7,278	4,628	4,198	4,253	3,907	3,301	2,823	1,073	429	368	-	-
Cashflow From Investing	-4336.0%	-36,065	-813	-7,771	-1,790	-46,895	-32,445	-22,447	-40,045	-	-93.00	-201	-100,004	-2,000	-	-	-	-	-
Cashflow From Financing	2.9%	-53,523	-55,099	-339	3,409	2,658	2,050	750	1,383	7,072	-313	648	12.00	-1,156	136,622	-67.00	73,762	-	-
Buy Backs	-1.1%	50,000	50,543	-	-	-	-	-	-	-	-	-	-	-	-	167	-	-	-

HRMY Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
Net product revenue	$ 582,022	$ 437,855	$ 305,440
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of product sold	$ 121,236	$ 83,481	$ 55,518
Cost, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Gross profit	$ 460,786	$ 354,374	$ 249,922
Operating expenses:
Research and development	76,063	70,886	30,367
Sales and marketing	97,404	79,285	68,118
General and administrative	95,289	84,017	63,909
Total operating expenses	268,756	234,188	162,394
Operating income	192,030	120,186	87,528
Loss on debt extinguishment	(9,766)		(26,146)
Other (expense) income, net	159	169	16
Interest expense	(23,757)	(18,795)	(24,194)
Interest income	14,730	3,126	224
Income before income taxes	173,396	104,686	37,428
Income tax (expense) benefit	(44,543)	76,782	(2,831)
Net income	128,853	181,468	34,597
Unrealized income (loss) on investments	153	(151)
Comprehensive income	$ 129,006	$ 181,317	$ 34,597
EARNINGS PER SHARE:
Basic	$ 2.17	$ 3.07	$ 0.60
Diluted	$ 2.13	$ 2.97	$ 0.58
Weighted average number of shares of common stock - basic	59,469,648	59,173,121	57,531,540
Weighted average number of shares of common stock - diluted	60,372,397	61,097,045	59,205,213

HRMY Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 311,660	$ 243,784
Investments, short-term	41,800	79,331
Trade receivables, net	74,140	54,740
Inventory, net	5,363	4,297
Prepaid expenses	12,570	9,347
Other current assets	5,537	8,786
Total current assets	451,070	400,285
NONCURRENT ASSETS:
Property and equipment, net	371	573
Restricted cash	270	750
Investments, long-term	72,169	22,568
Intangible assets, net	137,108	160,953
Deferred tax asset	144,162	85,943
Other noncurrent assets	6,298	2,798
Total noncurrent assets	360,378	273,585
TOTAL ASSETS	811,448	673,870
CURRENT LIABILITIES:
Trade payables	17,730	3,786
Accrued compensation	23,747	11,532
Accrued expenses	99,494	59,942
Current portion of long-term debt	15,000	2,000
Other current liabilities	7,810	1,624
Total current liabilities	163,781	78,884
NONCURRENT LIABILITIES:
Long-term debt, net	178,566	189,647
Other noncurrent liabilities	2,109	2,501
Total noncurrent liabilities	180,675	192,148
TOTAL LIABILITIES	344,456	271,032
COMMITMENTS AND CONTINGENCIES (Note 13)
STOCKHOLDERS' EQUITY:
Common stock-$0.00001 par value; 500,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 56,769,081 and 59,615,731 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	1	1
Additional paid in capital	610,266	675,118
Accumulated other comprehensive (loss) income	2	(151)
Accumulated deficit	(143,277)	(272,130)
TOTAL STOCKHOLDERS' EQUITY	466,992	402,838
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 811,448	$ 673,870

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

CEO	Dr. Jeffrey M. Dayno M.D.
WEBSITE	harmonybiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	200

Harmony Biosciences Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Harmony Biosciences Holdings, Inc.? What does HRMY stand for in stocks?

HRMY is the stock ticker symbol of Harmony Biosciences Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Harmony Biosciences Holdings, Inc. (HRMY)?

As of Fri Apr 19 2024, market cap of Harmony Biosciences Holdings, Inc. is 1.67 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HRMY stock?

You can check HRMY's fair value in chart for subscribers.

What is the fair value of HRMY stock?

You can check HRMY's fair value in chart for subscribers. The fair value of Harmony Biosciences Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Harmony Biosciences Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HRMY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Harmony Biosciences Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether HRMY is over valued or under valued. Whether Harmony Biosciences Holdings, Inc. is cheap or expensive depends on the assumptions which impact Harmony Biosciences Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HRMY.

What is Harmony Biosciences Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, HRMY's PE ratio (Price to Earnings) is 12.95 and Price to Sales (PS) ratio is 2.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HRMY PE ratio will change depending on the future growth rate expectations of investors.